1921
Volume 102 Number 2s
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

    oa A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool

  • The Ivermectin Roadmappers1
  • View Affiliations Hide Affiliations
    *Address correspondence to Carlos Chaccour, Barcelona Institute for Global Health (ISGlobal), Rosello 132, Barcelona 08036, Spain. E-mail: carlos.chaccour@isglobal.org

    Disclosure: PB reports personal fees from Sanaria Inc., outside the submitted work BF has a patent 16/275,172 pending, and JJ advises the non-for-profit Foundation Mundo Sano on public health use of ivermectin-albendazole combination therapy. NRR, CCh, PRC, and MGS received funding from BMG for the development of this roadmap. NRR, CCh, and PRC are engaged in the BOHEMIA project (with funding from Unitaid) to evaluate ivermectin MDA to humans and livestock in Africa and, if results are positive, facilitate policy recommendation and national adoption. Part of their salary was funded by the BOHEMIA grant from Unitaid to ISGlobal. CCh was supported by a Ramón Areces fellowship. CJ reports part of her salary funded since February 2019 by a Unitaid grant through the University of Oxford for the BOHEMIA project. FR was a member of the Mectizan Expert Committee (MEC) at the Task Force for Global Health (TFGH) from May 2017–May 2019. Mectizan is the Merck & Co. brand name for their ivermectin tablet product that is donated to onchocerciasis and lymphatic filariasis programs. The MEC advises the TFGH Mectizan Donation Program that is involved in providing the Merck donation. SR works at IVCC, which is supported by the BMGF. RZ is supported by the President’s Malaria Initiative.

    Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the President’s Malaria Initiative.

    fn1  PB, CCh, BF, MGS, JJ, PK, KK, AL, JL, DM, LM, ChM, NRR, FR, CR, JR, PRC, HS, KX, and RZ.

    fn2   PB, CCh, BF, MGS, JJ, PK, KK, NRR, CR, PRC, KX, and RZ.

    fn3   CCh, BF, JJ, GJ, PK, KK, SM, DO, NRR, SR, FR, CR, JR, FS, HS, and RZ.

    fn4   PB, CCh, BF, MGS, GJ, KK, AL, JL, DM, LM, ChM, NRR, FR, CR, JR, HS, KX, and RZ.

    fn5Financial support: Funding for the development of this roadmap was provided by the Bill & Melinda Gates Foundation. ISGlobal is a member of the CERCA Program, Generalitat de Catalunya.

    Notes

  • Publisher: The American Society of Tropical Medicine and Hygiene
  • Source: The American Journal of Tropical Medicine and Hygiene, Volume 102, Issue 2s, 6 Feb 2020, p. 3 - 24
  • DOI: https://doi.org/10.4269/ajtmh.19-0620

Abstract

Abstract.

In the context of stalling progress against malaria, resistance of mosquitoes to insecticides, and residual transmission, mass drug administration (MDA) of ivermectin, an endectocide used for neglected tropical diseases (NTDs), has emerged as a promising complementary vector control method. Ivermectin reduces the life span of mosquitoes that feed on treated humans and/or livestock, potentially decreasing malaria parasite transmission when administered at the community level. Following the publication by WHO of the preferred product characteristics for endectocides as vector control tools, this roadmap provides a comprehensive view of processes needed to make ivermectin available as a vector control tool by 2024 with a completely novel mechanism of action. The roadmap covers various aspects, which include 1) the definition of optimal dosage/regimens for ivermectin MDA in both humans and livestock, 2) the risk of resistance to the drug and environmental impact, 3) ethical issues, 4) political and community engagement, 5) translation of evidence into policy, and 6) operational aspects of large-scale deployment of the drug, all in the context of a drug given as a prevention tool acting at the community level. The roadmap reflects the insights of a multidisciplinary group of global health experts who worked together to elucidate the path to inclusion of ivermectin in the toolbox against malaria, to address residual transmission, counteract insecticide resistance, and contribute to the end of this deadly disease.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0620
2020-02-06
2020-07-05
Loading full text...

Full text loading...

/deliver/fulltext/14761645/102/2s/tpmd190620.html?itemId=/content/journals/10.4269/ajtmh.19-0620&mimeType=html&fmt=ahah

References

  1. WHO, World Malaria Report 2018. Available at: https://www.who.int/malaria/publications/world-malaria-report-2018/en/. Accessed November 26, 2019.
    [Google Scholar]
  2. Bhatt S et al., 2015. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 526: 207211.
    [Google Scholar]
  3. WHO, World Malaria Report 2017. Available at: http://apps.who.int/iris/bitstream/10665/259492/1/9789241565523-eng.pdf?ua=1. Accessed November 29, 2017.
    [Google Scholar]
  4. WHO, 2016. WHO Malaria Terminology. Geneva, Switzerland: World Health Organization, Available at: http://apps.who.int/iris/bitstream/10665/208815/1/WHO_HTM_GMP_2016.6_eng.pdf. Accessed November 26, 2019.
    [Google Scholar]
  5. WHO, 2016. Global Technical Strategy for Malaria 2016-2030. Available at: http://www.who.int/malaria/areas/global_technical_strategy/en/. Accessed September 27, 2018.
    [Google Scholar]
  6. Rabinovich RN et al., 2017. malERA: an updated research agenda for malaria elimination and eradication. PLoS Med 14: e1002456.
    [Google Scholar]
  7. Omura S, Crump A, 2014. Ivermectin: panacea for resource-poor communities? Trends Parasitol 30: 445455.
    [Google Scholar]
  8. Richards FO Jr., 2017. Upon entering an age of global ivermectin-based integrated mass drug administration for neglected tropical diseases and malaria. Malar J 16: 168.
    [Google Scholar]
  9. Chaccour C, Killeen GF, 2016. Mind the gap: residual malaria transmission, veterinary endectocides and livestock as targets for malaria vector control. Malar J 15: 24.
    [Google Scholar]
  10. Chaccour CJ, Kobylinski KC, Bassat Q, Bousema T, Drakeley C, Alonso P, Foy BD, 2013. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination. Malar J 12: 153.
    [Google Scholar]
  11. Foy BD, Kobylinski KC, da Silva IM, Rasgon JL, Sylla M, 2011. Endectocides for malaria control. Trends Parasitol 27: 423428.
    [Google Scholar]
  12. Fritz ML, Siegert PY, Walker ED, Bayoh MN, Vulule JR, Miller JR, 2009. Toxicity of bloodmeals from ivermectin-treated cattle to Anopheles gambiae s.l. Ann Trop Med Parasitol 103: 539547.
    [Google Scholar]
  13. Pampiglione S, Majori G, Petrangeli G, Romi R, 1985. Avermectins, MK-933 and MK-936, for mosquito control. Trans R Soc Trop Med Hyg 79: 797799.
    [Google Scholar]
  14. Bockarie MJ, Hii JL, Alexander ND, Bockarie F, Dagoro H, Kazura JW, Alpers MP, 1999. Mass treatment with ivermectin for filariasis control in Papua New Guinea: impact on mosquito survival. Med Vet Entomol 13: 120123.
    [Google Scholar]
  15. Chaccour C, Lines J, Whitty CJ, 2010. Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. J Infect Dis 202: 113116.
    [Google Scholar]
  16. Rabinovich NR, 2018. Ivermectin: repurposing an old drug to complement malaria vector control. Lancet Infect Dis 18: 584585.
    [Google Scholar]
  17. Chaccour C, Hammann F, Rabinovich NR, 2017. Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. Malar J 16: 161.
    [Google Scholar]
  18. Chaccour C, Rabinovich NR, 2017. Ivermectin to reduce malaria transmission III. considerations regarding regulatory and policy pathways. Malar J 16: 162.
    [Google Scholar]
  19. Chaccour C, Rabinovich NR, 2017. Ivermectin to reduce malaria transmission II. considerations regarding clinical development pathway. Malar J 16: 166.
    [Google Scholar]
  20. WHO, 2016. WHO Preferred Product Characteristics: Endectocide for Malaria Transmission Control. Available at: http://www.who.int/malaria/publications/atoz/endectocide-transmission-control/en/. Accessed September 1, 2019.
    [Google Scholar]
  21. Chaccour CJ et al., 2015. Establishment of the ivermectin research for malaria elimination network: updating the research agenda. Malar J 14: 243.
    [Google Scholar]
  22. Chaccour CJ, Ngha'bi K, Abizanda G, Irigoyen Barrio A, Aldaz A, Okumu F, Slater H, Del Pozo JL, Killeen G, 2018. Targeting cattle for malaria elimination: marked reduction of Anopheles arabiensis survival for over six months using a slow-release ivermectin implant formulation. Parasit Vectors 11: 287.
    [Google Scholar]
  23. Fritz ML, Walker ED, Miller JR, 2012. Lethal and sublethal effects of avermectin/milbemycin parasiticides on the African malaria vector, Anopheles arabiensis. J Med Entomol 49: 326331.
    [Google Scholar]
  24. Imbahale SS, Montana Lopez J, Brew J, Paaijmans K, Rist C, Chaccour C, 2019. Mapping the potential use of endectocide-treated cattle to reduce malaria transmission. Sci Rep 9: 5826.
    [Google Scholar]
  25. Pooda HS et al., 2015. Administration of ivermectin to peridomestic cattle: a promising approach to target the residual transmission of human malaria.Malar J 13 (Suppl 1): 496.
    [Google Scholar]
  26. Merck_&_Co., Stromectrol, 2014. TGA-Australia Approved Package Insert 2014. Available at: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02659-3&d=2016071016114622483. Accessed November 26, 2019.
    [Google Scholar]
  27. Bellinger AM et al., 2016. Oral, ultra-long-lasting drug delivery: application toward malaria elimination goals. Sci Transl Med 8: 365ra157.
    [Google Scholar]
  28. Slater HC, Walker PG, Bousema T, Okell LC, Ghani AC, 2014. The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study. J Infect Dis 210: 19721980.
    [Google Scholar]
  29. Butters MP, Kobylinski KC, Deus KM, da Silva IM, Gray M, Sylla M, Foy BD, 2012. Comparative evaluation of systemic drugs for their effects against Anopheles gambiae. Acta Trop 121: 3443.
    [Google Scholar]
  30. Lyimo IN, Kessy ST, Mbina KF, Daraja AA, Mnyone LL, 2017. Ivermectin-treated cattle reduces blood digestion, egg production and survival of a free-living population of Anopheles arabiensis under semi-field condition in south-eastern Tanzania. Malar J 16: 239.
    [Google Scholar]
  31. Mendes AM, Albuquerque IS, Machado M, Pissarra J, Meireles P, Prudencio M, 2017. Inhibition of Plasmodium liver infection by ivermectin. Antimicrob Agents Chemother 61: e02005e02016.
    [Google Scholar]
  32. de Carvalho LP, Sandri TL, Jose Tenorio de Melo E, Fendel R, Kremsner PG, Mordmuller B, Held J, 2019. Ivermectin impairs the development of sexual and asexual stages of Plasmodium falciparum in vitro. Antimicrob Agents Chemother 63: e00085-19.
    [Google Scholar]
  33. Smit MR et al., 2019. Pharmacokinetics-pharmacodynamics of high-dose ivermectin with dihydroartemisinin-piperaquine on mosquitocidal activity and QT-prolongation (IVERMAL). Clin Pharmacol Ther 105: 388401.
    [Google Scholar]
  34. Edwards G, 2003. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J 2 (Suppl 1): S8.
    [Google Scholar]
  35. Merck_&_Co., Stromectrol, 2009. FDA Approved Package Insert 2009. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050742s026lbl.pdf. Accessed November 26, 2019.
    [Google Scholar]
  36. Ministere des Affaires Sociales de la Sante et des Droits des Femmes, Stromectol 3 mg, comprimé - Résumé des caractéristiques du produit. Available at: http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=61350360&typedoc=R. Accessed November 26, 2019.
    [Google Scholar]
  37. Smit MR et al., 2018. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 18: 615626.
    [Google Scholar]
  38. Barry A et al., 2018. Optimal mode for delivery of seasonal malaria chemoprevention in Ouelessebougou, Mali: a cluster randomized trial. PLoS One 13: e0193296.
    [Google Scholar]
  39. Goss CW et al., 2019. Dosing pole recommendations for lymphatic filariasis elimination: a height-weight quantile regression modeling approach. PLoS Negl Trop Dis 13: e0007541.
    [Google Scholar]
  40. Chaccour C, Abizanda G, Irigoyen A, Del Pozo JL, 2016. Slow release ivermectin formulation for malaria control: a pilot study in 80-kg pigs. Antimicrob Agents Chemother.
    [Google Scholar]
  41. Chaccour C, Barrio A, Gil Royo AG, Martinez Urbistondo D, Slater H, Hammann F, Del Pozo JL, 2015. Screening for an ivermectin slow-release formulation suitable for malaria vector control. Malar J 14: 102.
    [Google Scholar]
  42. Miglianico M et al., 2018. Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases. Proc Natl Acad Sci USA 115: E6920E6926.
    [Google Scholar]
  43. FDA, Animal Drug Safety Communication: FDA Alerts Pet Owners and Veterinarians about Potential for Neurologic Adverse Events Associated with Certain Flea and Tick Products. Available at: https://www.fda.gov/animal-veterinary/cvm-updates/animal-drug-safety-communication-fda-alerts-pet-owners-and-veterinarians-about-potential-neurologic. Accessed November 26, 2019.
    [Google Scholar]
  44. Kiware SS, Chitnis N, Devine GJ, Moore SJ, Majambere S, Killeen GF, 2012. Biologically meaningful coverage indicators for eliminating malaria transmission. Biol Lett 8: 874877.
    [Google Scholar]
  45. Foy BD et al., 2019. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet 393: 15171526.
    [Google Scholar]
  46. Bradley J, Moulton LH, Hayes R, 2019. Analysis of the RIMDAMAL trial. Lancet 394: 10051006.
    [Google Scholar]
  47. Foy BD, Rao S, Parikh S, Slater HC, Dabire RK, 2019. Analysis of the RIMDAMAL trial - authors’ reply. Lancet 394: 10061007.
    [Google Scholar]
  48. Mectizan Donation Program Annual Highlights 2017. Available at: https://mectizan.org/wp-content/uploads/2018/06/MDP_AH17_English.pdf. Accessed October 16, 2018.
    [Google Scholar]
  49. Chippaux JP, Gardon-Wendel N, Gardon J, Ernould JC, 1993. Absence of any adverse effect of inadvertent ivermectin treatment during pregnancy. Trans R Soc Trop Med Hyg 87: 318.
    [Google Scholar]
  50. Doumbo O, Soula G, Kodio B, Perrenoud M, 1992. Ivermectin and pregnancy in mass treatment in Mali. Bull Soc Pathol Exot 85: 247251.
    [Google Scholar]
  51. Gyapong JO, Chinbuah MA, Gyapong M, 2003. Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis. Trop Med Int Health 8: 10931101.
    [Google Scholar]
  52. Makene C, Malecela M, Kabali C, Charles E, Swai E, Lekashingo L ea, 2003. Inadvertent Treatment of Pregnant Women in the Tanzanian Mass Drug Administration Program for the Elimination of Lymphatic Filariasis. 52nd Annual Meeting and Centennial Celebration, December 3, 2003. Philadelphia, PA: ASTMH, 77.
    [Google Scholar]
  53. Ndyomugyenyi R, Kabatereine N, Olsen A, Magnussen P, 2008. Efficacy of ivermectin and albendazole alone and in combination for treatment of soil-transmitted helminths in pregnancy and adverse events: a randomized open label controlled intervention trial in Masindi district, western Uganda. Am J Trop Med Hyg 79: 856863.
    [Google Scholar]
  54. Pacque M, Munoz B, Poetschke G, Foose J, Greene BM, Taylor HR, 1990. Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution. Lancet 336: 14861489.
    [Google Scholar]
  55. Wilkins AL, Steer AC, Cranswick N, Gwee A, 2018. Question 1: is it safe to use ivermectin in children less than five years of age and weighing less than 15 kg? Arch Dis Child 103: 514519.
    [Google Scholar]
  56. Kamgno J et al., 2017. A test-and-not-treat strategy for onchocerciasis in Loa loa-endemic areas. N Engl J Med 377: 20442052.
    [Google Scholar]
  57. Zeng Z, Andrew NW, Arison BH, Luffer-Atlas D, Wang RW, 1998. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica 28: 313321.
    [Google Scholar]
  58. WHO, 2000. Malaria Transmission Blocking Vaccines: an Ideal Public Good. Geneva, Switzerland: World Health Organization.
    [Google Scholar]
  59. Riviere JE, Papich MGV, 2013. Veterinary Pharmacology and Therapeutics. Wiley-Blackwell.
    [Google Scholar]
  60. Pasay CJ et al., 2019. Treatment of pigs with endectocides as a complementary tool for combating malaria transmission by Anopheles farauti (s.s.) in Papua New Guinea. Parasit Vectors 12: 124.
    [Google Scholar]
  61. WHO, 2014. Evaluation of Certain Veterinary Drug Residues in Food: Seventy-Eighth Report of the Joint FAO/WHO Expert Committee on Food Additives. Available at: http://apps.who.int/iris/bitstream/10665/127845/1/9789241209885_eng.pdf. Accessed November 26, 2019.
    [Google Scholar]
  62. Lozano-Fuentes S, Kading RC, Hartman DA, Okoth E, Githaka N, Nene V, Poche RM, 2016. Evaluation of a topical formulation of eprinomectin against Anopheles arabiensis when administered to zebu cattle (Bos indicus) under field conditions. Malar J 15: 324.
    [Google Scholar]
  63. Griffin JT et al., 2016. Potential for reduction of burden and local elimination of malaria by reducing Plasmodium falciparum malaria transmission: a mathematical modelling study. Lancet Infect Dis 16: 465472.
    [Google Scholar]
  64. White MT, Conteh L, Cibulskis R, Ghani AC, 2011. Costs and cost-effectiveness of malaria control interventions–a systematic review. Malar J 10: 337.
    [Google Scholar]
  65. Burnham G, 2007. Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet 370: 1125.
    [Google Scholar]
  66. Cupp E, Richards F, Lammie P, Eberhard M, 2007. Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet 370: 1123; author reply 11241125.
    [Google Scholar]
  67. Mackenzie CD, 2007. Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet 370: 1123; author reply 11241125.
    [Google Scholar]
  68. Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK, 2007. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 369: 20212029.
    [Google Scholar]
  69. Kobylinski KC, Alout H, Foy BD, Clements A, Adisakwattana P, Swierczewski BE, Richardson JH, 2014. Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control. Am J Trop Med Hyg 91: 655662.
    [Google Scholar]
  70. Chen LP, Wang P, Sun YJ, Wu YJ, 2016. Direct interaction of avermectin with epidermal growth factor receptor mediates the penetration resistance in Drosophila larvae. Open Biol 6: 150231.
    [Google Scholar]
  71. Wang X, Wang R, Yang Y, Wu S, O'Reilly AO, Wu Y, 2016. A point mutation in the glutamate-gated chloride channel of Plutella xylostella is associated with resistance to abamectin. Insect Mol Biol 25: 116125.
    [Google Scholar]
  72. Xu Z et al., 2017. High gama-aminobutyric acid contents involved in abamectin resistance and predation, an interesting phenomenon in spider mites. Front Physiol 8: 216.
    [Google Scholar]
  73. Luo L, Sun YJ, Wu YJ, 2013. Abamectin resistance in Drosophila is related to increased expression of P-glycoprotein via the dEGFR and dAkt pathways. Insect Biochem Mol Biol 43: 627634.
    [Google Scholar]
  74. Mangia C, Vismarra A, Kramer L, Bell-Sakyi L, Porretta D, Otranto D, Epis S, Grandi G, 2016. Evaluation of the in vitro expression of ATP binding-cassette (ABC) proteins in an Ixodes ricinus cell line exposed to ivermectin. Parasit Vectors 9: 215.
    [Google Scholar]
  75. Gao X, Yang J, Xu B, Xie W, Wang S, Zhang Y, Yang F, Wu Q, 2016. Identification and characterization of the gene CYP340W1 from Plutella xylostella and its possible involvement in resistance to abamectin. Int J Mol Sci 17: 274.
    [Google Scholar]
  76. Chosidow O, Giraudeau B, Cottrell J, Izri A, Hofmann R, Mann SG, Burgess I, 2010. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. N Engl J Med 362: 896905.
    [Google Scholar]
  77. Cochran DG, 1990. Efficacy of abamectin fed to German cockroaches (Dictyoptera: Blattellidae) resistant to pyrethroids. J Econ Entomol 83: 12431245.
    [Google Scholar]
  78. Roush RT, Wright JE, 1986. Abamectin: toxicity to house flies (Diptera: Muscidae) resistant to synthetic organic insecticides. J Econ Entomol 79: 562564.
    [Google Scholar]
  79. Strycharz JP, Yoon KS, Clark JM, 2008. A new ivermectin formulation topically kills permethrin-resistant human head lice (Anoplura: Pediculidae). J Med Entomol 45: 7581.
    [Google Scholar]
  80. Deus KM, Saavedra-Rodriguez K, Butters MP, WCt Black, Foy BD, 2012. The effect of ivermectin in seven strains of Aedes aegypti (Diptera: Culicidae) including a genetically diverse laboratory strain and three permethrin resistant strains. J Med Entomol 49: 356363.
    [Google Scholar]
  81. Kim JH, Gellatly KJ, Lueke B, Kohler M, Nauen R, Murenzi E, Yoon KS, Clark JM, 2018. Detoxification of ivermectin by ATP binding cassette transporter C4 and cytochrome P450 monooxygenase 6CJ1 in the human body louse, Pediculus humanus humanus. Insect Mol Biol 27: 7382.
    [Google Scholar]
  82. Pohl PC, Klafke GM, Carvalho DD, Martins JR, Daffre S, da Silva Vaz I Jr., Masuda A, 2011. ABC transporter efflux pumps: a defense mechanism against ivermectin in Rhipicephalus (Boophilus) microplus. Int J Parasitol 41: 13231333.
    [Google Scholar]
  83. Yoon KS, Strycharz JP, Baek JH, Sun W, Kim JH, Kang JS, Pittendrigh BR, Lee SH, Clark JM, 2011. Brief exposures of human body lice to sublethal amounts of ivermectin over-transcribes detoxification genes involved in tolerance. Insect Mol Biol 20: 687699.
    [Google Scholar]
  84. Alout H et al., 2014. Evaluation of ivermectin mass drug administration for malaria transmission control across different west African environments. Malar J 13: 417.
    [Google Scholar]
  85. Liebig M et al., 2010. Environmental risk assessment of ivermectin: a case study. Integr Environ Assess Manag 6 (Suppl): 567587.
    [Google Scholar]
  86. FDA, Antiparasitic Resistance in Cattle and Small Ruminants in the United States:How to Detect it and what to Do about it. Available at: https://www.fda.gov/downloads/AnimalVeterinary/ResourcesforYou/UCM347442.pdf. Accessed November 26, 2019.
    [Google Scholar]
  87. Adler NE, Koschorreck J, Rechenberg B, 2008. Environmental impact assessment and control of pharmaceuticals: the role of environmental agencies. Water Sci Technol 57: 9197.
    [Google Scholar]
  88. Tenywa FC, Kambagha A, Saddler A, Maia MF, 2017. The development of an ivermectin-based attractive toxic sugar bait (ATSB) to target Anopheles arabiensis. Malar J 16: 338.
    [Google Scholar]
  89. Malima R et al., 2017. Experimental hut evaluation of a novel long-lasting non-pyrethroid durable wall lining for control of pyrethroid-resistant Anopheles gambiae and Anopheles funestus in Tanzania. Malar J 16: 82.
    [Google Scholar]
  90. WHO, Prequalification Vector Control: Determination of Pathway. Available at: http://www.who.int/pq-vector-control/resources/pathway/en/. Accessed January 15, 2018.
    [Google Scholar]
  91. WHO, 2017. The Evaluation Process for Vector Control Products. Available at: http://apps.who.int/iris/bitstream/10665/255644/1/WHO-HTM-GMP-2017.13-eng.pdf?ua=1.
    [Google Scholar]
  92. WHO, VCAG Assessment of New Products. Available at: http://www.who.int/neglected_diseases/vector_ecology/VCAG_submission/en/. Accessed January 15, 2018.
    [Google Scholar]
  93. WHO, 2016. Fourth Meeting of the Vector Control Advisory Group (VCAG). Available at: http://www.who.int/neglected_diseases/vector_ecology/resources/9789241511100/en/. Accessed January 15, 2018.
    [Google Scholar]
  94. WHO, 2017. Design of Epidemiological Trials for Vector Control Products, Report of a WHO Expert Advisory Group, Chateau de Penthes, Geneva, 24–25 April 2017. Geneva, Switzerland: World Health Organization.
    [Google Scholar]
  95. Romani L et al., 2015. Mass drug administration for scabies control in a population with endemic disease. N Engl J Med 373: 23052313.
    [Google Scholar]
  96. WHO, 2017. Report of the Tenth Meeting of the WHO Strategic and Technical Advisory Group for Neglected Tropical Diseases. Available at: http://www.who.int/neglected_diseases/NTD_STAG_report_2017.pdf?ua=1. Accessed March 15, 2018.
    [Google Scholar]
  97. Keenan JD et al., 2018. Azithromycin to reduce childhood mortality in sub-Saharan Africa. N Engl J Med 378: 15831592.
    [Google Scholar]
  98. Liese BH, Wilson J, Benton B, Marr D, 1991. The Onchocerciasis Control Program in West Africa: a long-Term Commitment to Success. World Bank Policy Research Working Paper. Available at: http://documents.worldbank.org/curated/en/422141468768653052/pdf/multi0page.pdf. Accessed March 15, 2018.
    [Google Scholar]
  99. Frempong KK et al., 2016. Does increasing treatment frequency address suboptimal responses to ivermectin for the control and elimination of river blindness? Clin Infect Dis 62: 13381347.
    [Google Scholar]
  100. Waters HR, Rehwinkel JA, Burnham G, 2004. Economic evaluation of Mectizan distribution. Trop Med Int Health 9: A16A25.
    [Google Scholar]
  101. Gardner K, Meisch MV, Meek CL, Biven WS, 1993. Effects of ivermectin in canine blood on Anopheles quadrimaculatus, Aedes albopictus and Culex salinarius. J Am Mosq Control Assoc 9: 400402.
    [Google Scholar]
  102. Ouedraogo AL et al., 2015. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clin Infect Dis 60: 357365.
    [Google Scholar]
  103. Kobylinski KC, Deus KM, Butters MP, Hongyu T, Gray M, da Silva IM, Sylla M, Foy BD, 2010. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors. Acta Trop 116: 119126.
    [Google Scholar]
  104. Kobylinski KC, Foy BD, Richardson JH, 2012. Ivermectin inhibits the sporogony of Plasmodium falciparum in Anopheles gambiae. Malar J 11: 381.
    [Google Scholar]
  105. Kobylinski KC, Escobedo-Vargas KS, Lopez-Sifuentes VM, Durand S, Smith ES, Baldeviano GC, Gerbasi RV, Ballard SB, Stoops CA, Vasquez GM, 2017. Ivermectin susceptibility, sporontocidal effect, and inhibition of time to re-feed in the Amazonian malaria vector Anopheles darlingi. Malar J 16: 474.
    [Google Scholar]
  106. Sampaio VS et al., 2016. Filling gaps on ivermectin knowledge: effects on the survival and reproduction of Anopheles aquasalis, a Latin American malaria vector. Malar J 15: 491.
    [Google Scholar]
  107. Pinilla YT et al., 2018. Promising approach to reducing malaria transmission by ivermectin: sporontocidal effect against Plasmodium vivax in the South American vectors Anopheles aquasalis and Anopheles darlingi. PLoS Negl Trop Dis 12: e0006221.
    [Google Scholar]
  108. Pasay C, 2017. Investigating the Activity of the Macrocyclic Lactones Ivermectin and Moxidectin Against Malaria Vectors. Oral Presentation at the 66th Annual Meeting of ASTMH, Baltimore, MD, November 9, 2017.
    [Google Scholar]
  109. Dreyer SM, Morin KJ, Vaughan JA, 2018. Differential susceptibilities of Anopheles albimanus and Anopheles stephensi mosquitoes to ivermectin. Malar J 17: 148.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0620
Loading
/content/journals/10.4269/ajtmh.19-0620
Loading

Data & Media loading...

Supplemental Annex

  • Received : 22 Aug 2019
  • Accepted : 22 Oct 2019
  • Published online : 06 Feb 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error